Description
Modasmart (Modafinil) 200 mg
Modasmart 200 mg is a brand name for modafinil, a prescription wakefulness-promoting medicine. Verified regulatory sources describe modafinil as an oral tablet used to improve wakefulness in adults with certain sleep-wake disorders.
Active Ingredient and Medicine Class
The verified active ingredient is modafinil. It is classified as a wakefulness-promoting agent and is pharmacologically distinct from classic central nervous system stimulants.
Established Medical Uses
Official U.S. prescribing information states that modafinil is indicated to improve wakefulness in adults with narcolepsy, obstructive sleep apnea with residual excessive sleepiness, and shift work disorder. In obstructive sleep apnea, it is not a treatment for the underlying airway obstruction.
How It Works
The exact mechanism is not fully established. Modafinil is understood to promote wakefulness through effects on brain systems that regulate alertness, including dopaminergic and other wake-related pathways. It is used to reduce excessive daytime sleepiness rather than to treat the underlying cause of the sleep disorder.
Important Safety Information
Modafinil is contraindicated in patients with known hypersensitivity to modafinil or armodafinil. Prescribing information warns about serious skin reactions, including Stevens-Johnson syndrome, toxic epidermal necrolysis, and DRESS, as well as angioedema, anaphylaxis, and multi-organ hypersensitivity. It may also worsen psychiatric symptoms in susceptible patients.
Important interaction concerns include reduced effectiveness of hormonal contraception and interactions with other medicines metabolized through CYP pathways, including CYP3A4 induction and CYP2C19 inhibition. Caution is also advised in pregnancy and in patients with severe hepatic impairment.
Possible Side Effects
Common adverse effects reported with modafinil include headache, nausea, nervousness, insomnia, and anxiety. More serious reactions can include rash, allergic reactions, psychiatric symptoms, and cardiovascular effects in some patients.
Scientific Evidence
Peer-reviewed reviews and clinical trials support modafinil’s ability to reduce excessive sleepiness in narcolepsy and shift work disorder, with evidence also supporting its use as an adjunct in obstructive sleep apnea when sleepiness persists despite treatment of the underlying disorder. A clinical practice guideline from the American Academy of Sleep Medicine recommends modafinil for adult narcolepsy.
Medical Information Notice
This summary is based on sources available at the time of review and is intended for educational purposes only. It does not replace the official patient leaflet, product labeling, or assessment by a qualified healthcare professional.
Medical Sources
- DailyMed / U.S. National Library of Medicine: MODAFINIL tablet, prescribing information
- U.S. FDA: PROVIGIL (modafinil) tablets, full prescribing information
- Keating GM, et al. Modafinil: a review of its use in excessive sleepiness associated with obstructive sleep apnoea/hypopnoea syndrome and shift work sleep disorder. CNS Drugs. 2005.
